Search

everythinglearnresearchcommunity

for

Search:↓

Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.

Clinical trials should use innovative designs and biomarkers to improve precision therapy and patient outcomes.

PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.

EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.

The new formulation improved the skin absorption of the drug Thiocolchicoside.

A wearable device using NIR light may help treat hair loss non-invasively.

New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.

Nourella® effectively improves skin thickness and elasticity, reversing aging signs.

The treatment improved acne, seborrhoea, and hirsutism, with some side effects like spotting and nervousness.

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

Key genes and pathways involved in thyroid eye disease were identified, aiding potential treatment and diagnosis.

Deuruxolitinib improves anxiety and depression in severe alopecia areata patients.

Etrasimod is safe but not effective for severe alopecia areata, though it may help milder cases.

Auranofin shows promise as a cancer treatment, especially when combined with other therapies.

ENERGI-F701 solution was found to be more effective and safer than Regaine® 2% minoxidil solution in treating female pattern hair loss, with increased hair density and less side effects.

The nano-carrier makes etoposide safer and more effective against lung cancer.

The new gel improves skin delivery of a drug, potentially reducing dose frequency and side effects.

Ectoin helps prevent cortisone-induced skin problems and supports skin health.

Further testing of paclitaxel poliglumex for this cancer treatment is not justified.

The patient was satisfied with hormone therapy, and her epilepsy remained stable.

China approved Sinovac's flu vaccine, Japan approved RiUP for female hair loss, and Nippon Kayaku's three cancer drugs.

Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.

Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.

EK significantly improved wound healing and reduced infection in burn wounds.

Baricitinib-loaded EVs help hair regrowth in alopecia areata by reducing inflammation and promoting hair follicle regeneration.

The document suggests a need for collaboration, better evidence, and a responsible framework to safely and effectively advance regenerative therapies to clinical use.

Engineered extracellular vesicles can improve tissue repair and regeneration.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.